Trial Profile

A Phase 1 Open-Label Study of PF-07934040 as a Single Agent and in Combination With Other Targeted Agents in Participants With Advanced Solid Tumors Harboring Mutations in the KRAS Gene

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 21 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bevacizumab (Primary) ; Carboplatin (Primary) ; Cetuximab (Primary) ; Cisplatin (Primary) ; Fluorouracil (Primary) ; Folinic acid (Primary) ; Gemcitabine (Primary) ; Oxaliplatin (Primary) ; Paclitaxel (Primary) ; Pembrolizumab (Primary) ; Pemetrexed (Primary) ; PF 07934040 (Primary)
Indications Adenocarcinoma; Colorectal cancer; Non-small cell lung cancer; Pancreatic cancer; Pancreatic ductal carcinoma; Solid tumours
Focus Adverse reactions; Therapeutic Use
Sponsors Pfizer

16 Apr 2025 Planned End Date changed from 5 Aug 2028 to 23 Sep 2028.
16 Apr 2025 Planned primary completion date changed from 6 Aug 2027 to 24 Sep 2027.
25 Mar 2025 Planned End Date changed from 29 Jul 2028 to 5 Aug 2028.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com